This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Novo Nordisk (NVO)
by Derek Lewis
Novo Nordisk shares have been hot in 2023, up more than 19% and outperforming the S&P 500. Can momentum sustain?
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
by Zacks Equity Research
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
by Zacks Equity Research
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
by Zacks Equity Research
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
by Zacks Equity Research
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
by Zacks Equity Research
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
by Zacks Equity Research
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
Best Momentum Stocks to Buy for June 5th
by Zacks Equity Research
VIPS, KOF and NVO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2023.
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
New Strong Buy Stocks for June 5th
by Zacks Equity Research
NEM, KMT, VIPS, NVO and BAMXF have been added to the Zacks Rank #1 (Strong Buy) List on June 5, 2023.
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
by Zacks Equity Research
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Time to Buy Stock in These Pharmaceutical Giants for EPS Growth
by Shaun Pruitt
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
by Zacks Equity Research
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
by Zacks Equity Research
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Novo Nordisk (NVO) Announces Positive Obesity Program Data
by Zacks Equity Research
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
by Zacks Equity Research
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Pfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
by Zacks Equity Research
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Company News for May 23, 2023
by Zacks Equity Research
Companies in The News Are: GOOGL, PFE, NVO, CBRE, PG